A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas-Reference-Cited by-同舟云学术

A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas

Published:2013-11 Issue:6 Volume:55 Page:1288-1294
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Nabhan Chadi,Ollberding Nicholas J.,Villines Dana,Chiu Brian C.-H.,Caces Donne Bennett D.,Valdez Tina V.,Ghielmini Michele,Hsu Schmitz Shu-Fang,Smith Sonali M.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.839787

Reference37 articles.

1. New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma

2. Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis

3. Non-Hodgkin’s Lymphomas, Version 1.2013

4. Follicular Lymphoma Revisited

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Too much and not enough: revisiting maintenance rituximab in indolent lymphomas;Haematologica;2021-06-17

2. Chronic Benign CD8+ Proliferation: A Rare Affection that Can Mimic a Lymphoma Relapse;Case Reports in Hematology;2019-03-05

3. Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies;ACTA CLINICA CROATICA;2017

4. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era;Annals of Oncology;2016-05

5. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03;Journal of Clinical Oncology;2016-02-10